Login to Your Account

Alexion Files to Expand Soliris into aHUS Ahead of Schedule

By BioWorld Today Staff Reports

Friday, April 8, 2011
Alexion Pharmaceuticals Inc., of Cheshire, Conn, filed earlier-than-expected marketing applications in both the U.S. and Europe for Soliris (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription